Heparin-induced thrombocytopenia: why a low count clots
In heparin-induced thrombocytopenia (HIT), an antibody against PF4–heparin complexes lowers the platelet count and, at the same time, drives thrombin generation, so the danger is thrombosis, not bleeding.
Chapters (13)
Explain the PF4–heparin antibody mechanism of heparin-induced thrombocytopenia and why it causes thrombosis rather than bleeding.
The short version
- Heparin binds platelet factor 4 (PF4), and IgG against the PF4–heparin complex activates platelets.
- The platelet count falls, but thrombin generation surges, so the danger is clotting.
- The count typically falls 5 to 10 days after heparin starts, sooner if heparin was given in the last month.
- Score the odds with the 4Ts, screen with an immunoassay and confirm with the serotonin release assay.
- Stop all heparin and start a non-heparin anticoagulant.
The puzzle: low platelets and a clot on heparin
On day 6 of a heparin infusion, a patient's platelet count falls. You would expect bleeding. Instead her leg swells, because a new clot has formed.
Low platelets together with a clot is the central puzzle of heparin-induced thrombocytopenia (HIT). The rest of this lesson explains the mechanism, and why HIT causes thrombosis rather than bleeding.[1][2]
PF4, heparin and the IgG that binds the complex
Platelet factor 4 (PF4) is a small, positively charged protein stored in platelet alpha granules. Heparin is a long, negatively charged chain, so many PF4 molecules cluster around each chain.[1][2]
In some patients this changes the shape of PF4 and exposes a new epitope. The immune system sees it as foreign and makes IgG antibodies.[1]
Timing: 5 to 10 days, sooner with recent heparin
Antibodies take time, so the platelet count typically falls 5 to 10 days after heparin starts.[2][3]
If the patient had heparin in the last month, antibodies may already exist, and the fall can come within a day.[2][3]
How the antibody activates platelets and drives thrombin
The IgG binds the PF4–heparin complex, and its Fc end grips the FcγRIIa receptor on platelets. The platelets activate.[1][2]
- ActivationIgG–PF4–heparin complexes engage FcγRIIa and the platelets activate.[1][2]
- A loopActivated platelets degranulate, releasing more PF4, which builds more complexes.[1][4]
- Procoagulant surgePlatelets shed procoagulant microparticles, and monocytes, endothelial cells and neutrophils join in. Thrombin generation surges.[1][2]
That is the paradox. The platelet count falls, yet the blood is hypercoagulable, so the danger is thrombosis, not bleeding. Clots can threaten a limb or a life.[1][2]
The 4Ts score for heparin-induced thrombocytopenia
The 4Ts score estimates the odds of HIT: Thrombocytopenia, Timing, Thrombosis and oTher causes, scored 0 to 2 points each.[2][5]
| T | What scores 2 points |
|---|---|
| Thrombocytopenia | A fall of more than 50 %, with a nadir of at least 20 × 10⁹/L |
| Timing | Onset at 5 to 10 days, or within 1 day if heparin was given in the last 30 days |
| Thrombosis | New confirmed thrombosis, skin necrosis at an injection site, or an acute systemic reaction after an IV heparin bolus |
| oTher causes | No other cause |
| Total | Probability |
|---|---|
| 0–3 | Low |
| 4–5 | Intermediate |
| 6–8 | High |
- Platelets fall from 300 to 120 × 10⁹/L on day 7 (a fall of 60 %, nadir above 20): 2 points
- Onset on day 7, inside the 5-to-10-day window: 2 points
- New deep vein thrombosis: 2 points
- No other cause: 2 points
- 2 + 2 + 2 + 2 = 8, a high score
Tests, which heparins carry risk, and treatment
An immunoassay for anti-PF4–heparin antibodies is the screen. The serotonin release assay, a functional test, is the gold standard.[1][2]
Unfractionated heparin (UFH) carries more risk than low molecular weight heparin (LMWH), because short chains form far fewer large complexes. Fondaparinux forms essentially none.[1][4]
Treatment is to stop all heparin, including LMWH, and start a non-heparin anticoagulant such as argatroban, bivalirudin or fondaparinux.[1][5]
What HIT is not: TTP, ITP, DIC and type 1 HIT
| Condition | Key feature | Why it differs from HIT |
|---|---|---|
| TTP | ADAMTS13 deficiency lets ultralarge von Willebrand factor multimers form microthrombi; schistocytes on the smear[6][7] | Schistocytes, and no link to heparin |
| ITP | Autoantibody against platelet glycoproteins, with platelet destruction in the spleen; bruising and bleeding[8] | Bleeding rather than clots; heparin does not trigger it |
| DIC | Consumes clotting factors, so the PT is usually prolonged and fibrinogen often low[9] | A normal PT and fibrinogen argue against DIC |
| Type 1 HIT | Non-immune; milder and transient, appears in the first days and settles on its own[2][3] | No clots |
Practice question
Original · USMLE styleA 62-year-old woman receives subcutaneous unfractionated heparin for thromboprophylaxis after a total hip replacement. On postoperative day 8, her left calf becomes swollen and tender, and venous duplex ultrasonography shows a deep vein thrombosis. Her platelet count was 270 × 10⁹/L on admission and is now 88 × 10⁹/L. A peripheral blood smear shows no schistocytes. Her prothrombin time and plasma fibrinogen concentration are within the reference ranges.
Common questions
Why does heparin-induced thrombocytopenia cause clots rather than bleeding?
The IgG against PF4–heparin complexes activates platelets through FcγRIIa. Activated platelets shed procoagulant microparticles and thrombin generation surges, so the blood is hypercoagulable even though the count is low.
When does the platelet count fall in HIT?
Typically 5 to 10 days after heparin starts. If the patient had heparin in the last month, antibodies may already exist and the fall can come within a day.
What is the 4Ts score?
A score of 0 to 2 points for each of Thrombocytopenia, Timing, Thrombosis and oTher causes. A total of 0–3 is low, 4–5 intermediate and 6–8 high.
How is HIT diagnosed?
An immunoassay for anti-PF4–heparin antibodies is the screen. The serotonin release assay, a functional test, is the gold standard.
How is HIT treated?
Stop all heparin, including low molecular weight heparin, and start a non-heparin anticoagulant such as argatroban, bivalirudin or fondaparinux.
Transcript
Read the full narration, by chapter656 words
0:00The puzzle: low platelets and a clot on heparin
On day six of a heparin infusion, a patient's platelet count falls. You expect bleeding. Instead her leg swells, because a new clot has formed. Low platelets, and a clot. How can that be? Today: explain the PF4 heparin antibody mechanism of HIT, and why it causes thrombosis rather than bleeding. Platelet factor four,
0:23PF4, heparin and the IgG that binds the complex
PF4, is a small positively charged protein stored in platelet alpha granules. Heparin is a long, negatively charged chain, so many PF4 molecules cluster around each chain. In some patients this changes the shape of PF4 and exposes a new epitope. The immune system sees it as foreign and makes IgG antibodies. So the dangerous form, type two HIT, is immune-mediated. Type one is a separate, non-immune effect of heparin on platelets. Antibodies take time,
1:00Timing: 5 to 10 days, sooner with recent heparin
so the platelet count typically falls five to 10 days after heparin starts. If the patient had heparin in the last month, antibodies may already exist, and the fall can come within a day.
1:13Platelet activation: FcgammaRIIa, degranulation loop, thrombin surge
The IgG binds the PF4 heparin complex, and its Fc end grips the FcγRIIA receptor on platelets. The platelets activate. Activated platelets degranulate, releasing more PF4, which builds more complexes: a loop. They also shed procoagulant microparticles, and monocytes, endothelial cells and neutrophils join in. Thrombin generation surges.
1:42The paradox: thrombosis, not bleeding
That is the paradox. The platelet count falls, yet the blood is hypercoagulable, so the danger is thrombosis, not bleeding. Clots can threaten a limb or a life.
1:55The 4Ts score
The four T score estimates the odds: Thrombocytopenia, Timing, Thrombosis, and oTher causes, zero to two points each. Zero to three is low, four to five intermediate, six to eight high. A fall of more than 50%, onset at 5 to 10 days, new thrombosis, and no other cause each score two. An example: platelets fall from 300
2:20A worked 4Ts example
to 120 on day seven, with a new deep vein thrombosis and no other cause. Two, two, two, two: eight, a high score.
2:33Tests: immunoassay screen and serotonin release assay
An immunoassay for anti PF4 heparin antibodies is the screen. The serotonin release assay, a functional test, is the gold standard.
2:43UFH, LMWH and fondaparinux
Unfractionated heparin carries more risk than low molecular weight heparin, because short chains form far fewer large complexes. Fondaparinux forms essentially none. Treatment: stop all heparin,
2:55Treatment: stop all heparin, start a non-heparin anticoagulant
including low molecular weight heparin, and start a non-heparin anticoagulant, such as argatroban, bivalirudin or fondaparinux.
3:06Practice question
Your turn. A 62-year-old woman receives subcutaneous unfractionated heparin after a hip replacement. On day eight her left calf is swollen and tender, and ultrasound shows a deep vein thrombosis. Her platelet count was 270 on admission and is now 88. The blood smear shows no schistocytes, and her PT and fibrinogen are normal. Which of the following best explains the pathogenesis of her condition? A, IgG against platelet factor 4 heparin complexes, activating platelets. B, autoantibody against ADAMTS13, with ultralarge von Willebrand multimers. C, autoantibody against platelet glycoprotein IIb/IIIa, with splenic clearance. D, tissue factor release, with widespread consumption of clotting factors. E, direct non-immune platelet activation caused by heparin. Pause here and decide.
4:12Answer and explanation
B is out: that is TTP, which shows schistocytes, and has no link to heparin. C is out: immune thrombocytopenia destroys platelets and causes bruising and bleeding rather than clots, and heparin does not trigger it. D is out: DIC consumes clotting factors, so the PT and fibrinogen would be abnormal. E is out: the non-immune type one effect is mild, appears in the first days, settles on its own and does not cause clots. A fall to 88 on day eight with a clot points to the immune type. So the answer is A. A fall at 5 to 10 days, new thrombosis, and an otherwise normal screen: immune-mediated HIT. Three things to keep.
5:01Recap and next lesson
One: heparin binds PF4, and IgG against the complex activates platelets. Two: platelets fall, but thrombin surges, so the danger is clotting. Three: score it with the four T's, stop all heparin, and start a non-heparin anticoagulant. Next, DIC versus TTP versus HUS.
Sources
Numbers in the text, e.g. [1], point here- Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management. J Clin Med. 2021. europepmc.org/article/PMC/PMC7916628
- Heparin-induced thrombocytopenia (review). Thromb J. 2021. europepmc.org/article/PMC/PMC8443112
- Heparin induced thrombocytopenia: case presentation and review. J Clin Med Res. 2012. europepmc.org/article/PMC/PMC3279506
- Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of HIT. Thromb J. 2013. europepmc.org/article/PMC/PMC3627638
- 4Ts score and HIT management (open-access reviews). europepmc.org/article/PMC/PMC12232505 · europepmc.org/article/PMC/PMC13194571
- Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021. europepmc.org/article/PMC/PMC7867179
- Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol. 2022. europepmc.org/article/PMC/PMC9544907
- Primary Immune Thrombocytopenia. J Clin Med. 2021. europepmc.org/article/PMC/PMC7920457 · europepmc.org/article/PMC/PMC10889445
- Disseminated intravascular coagulation. LITFL. litfl.com/disseminated-intravascular-coagulation/
The platelet-count graphs and the 300 to 120 worked example are teaching models with illustrative values.
The practice question is original and its patient is synthetic. Every fact is checked against the sources above in independent accuracy reviews. Always follow your local guidelines and your own laboratory’s ranges.
Image credits. Illustrations: Servier Medical Art (smart.servier.com), CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), adapted (cropped, recoloured, outlined): venous thrombosis, lower leg, IgG, laboratory tube, syringe, spleen, monocyte. NIAID NIH BioArt Source (bioart.niaid.nih.gov), public domain: neutrophil, endothelial cell, von Willebrand factor. Health Icons (healthicons.org), CC0: intravenous drip. The platelet, PF4, heparin, IgG and receptor schematics, the graphs and all handwriting are drawn in code (original).
Corrections. None so far. Spotted an error? Email info@medservatory.com with the lesson code MS-S1-HEME-014.
For exam study only, not medical advice. Read the medical disclaimer.
In this series
Playlist on YouTube- EP 01Microcytic anaemia: four causes, four iron fingerprints5:37
- EP 02Hepcidin: why iron falls in inflammation5:34
- EP 03B12 vs folate deficiency: MMA, homocysteine and the nerves5:23
- EP 04Intravascular vs extravascular haemolysis: site and labs5:27
- EP 05G6PD deficiency vs hereditary spherocytosis, by mechanism5:36
- EP 06Sickle cell disease pathophysiology: HbS to vaso-occlusion5:26
- EP 07Primary haemostasis: platelet adhesion, activation and aggregation5:53
- EP 08Coagulation cascade: PT vs aPTT, pathway by pathway5:21
- EP 09Von Willebrand disease vs haemophilia: the labs that separate them5:32
- EP 10Anticoagulants: target, monitoring test and reversal agent5:34
- EP 11Heparin-induced thrombocytopenia: why a low count clots5:29
- EP 12DIC vs TTP vs HUS: mechanism and the PT/PTT5:33
- EP 13AML vs ALL vs CML vs CLL: leukemia classification made simple5:44
- EP 14Oncogenes vs tumour suppressor genes: one hit or two5:17